Form 4: Gilead Sciences' Chief Medical Officer, Merdad Parsey, Reports Stock Transactions
SEC Form 4 Filing
Merdad Parsey, Chief Medical Officer of Gilead Sciences, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
Summary
- On September 10, 2024, Merdad Parsey, the Chief Medical Officer of Gilead Sciences, Inc., engaged in transactions involving the company's common stock.
- Specifically, 3,821 restricted stock units vested, converting into an equal number of common stock shares.
- Following the vesting, Parsey disposed of 1,766 shares at a price of $81.44 per share to satisfy tax obligations.
- After these transactions, Parsey directly owns 98,435 shares of Gilead Sciences common stock and 40,573 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral filing, simply reporting required information about stock transactions by an executive. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates activity by a high-ranking executive at Gilead Sciences, which is typical for companies with equity-based compensation plans.
Key Dates
| Date | Description |
|---|---|
| 09/10/2024 | Date of stock transactions: vesting of restricted stock units and sale of shares. |
| 09/11/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.